September 13, 2024
Gustav Ullenhag, principal investigator of the LOKON003 trial presented the study at ESMO in Barcelona. In this study, LOAd703 TME gene engineering was used for patients with malignant melanoma in combination with PD-1/PD-L1 blockade.
